Source comparison
Melanotan-1 for Sunless Tanning: Research Applications Comparison
Photoprotection research (EPP patients) 16mg subcutaneous implant (Scenesse) Once every 60 days Visible pigmentation 7–10 days; peak effect 30–40 days Gold-standard clinical model. FDA-approved with extensive safety data spanning 10+ years Melanogenesis pathwa
This comparison does not assign a generated winner or score.
- Photoprotection research (EPP patients)
- 16mg subcutaneous implant (Scenesse)
- Once every 60 days
- Visible pigmentation 7–10 days; peak effect 30–40 days
- Gold-standard clinical model. FDA-approved with extensive safety data spanning 10+ years
- Melanogenesis pathway studies
- 0.1–0.2mg/kg subcutaneous injection
- 3× weekly for 2–4 weeks
- Dose-dependent melanin increases measurable by spectrophotometry within 5–7 days
- Allows precise control of MC1R activation independent of UV variables. Ideal for mechanistic studies
- Dermatological photoaging research
- 0.16mg/kg subcutaneous injection
- Every other day for 30–60 days
- Epidermis thickening and melanin density increases within 14–21 days
- Demonstrates melanin's role as a UV filter and antioxidant. Separates pigmentation from direct DNA damage
- Cosmetic tanning (non-clinical)
- 0.5–1mg subcutaneous injection
- Daily during loading phase, then 2–3× weekly maintenance
- Noticeable colour change 3–5 days; significant darkening 10–14 days
- Unregulated use with minimal safety monitoring. Off-label application lacks long-term outcome data
- The most reliable research outcomes consistently use subcutaneous administration in the abdominal or thigh region with a 29- or 30-gauge insulin syringe. Intranasal formulations were investigated in early Melanotan-2 studies but produced inconsistent absorption and higher rates of nausea. Intramuscular injection is unnecessary. The peptide's mechanism of action is systemic receptor binding, not local tissue effect, so route of entry matters only for pharmacokinetic consistency.